The enhanced expression of proinflammatory cytokines and chemokines accompanies brain injury induced by neurotrauma, disease or neurotoxicity as well as systemic infection. Elevations in proinflammatory mediators may serve as modulators or mediators of astroglial and microglial activation, cellular responses associated with all types of brain injury and collectively referred to as neuroinflammation. The "acute phase" response to systemic inflammation also leads to upregulation of proinflammatory cytokines/chemokines in the brain in the absence of underling neural damage, responses thought to be mediated largely by microglia and that serve as the basis of "sickness behavior". Activated glia may have neuroprotective roles or may exacerbate neural damage. Exposure to the known dopaminergic damage followed by neuroinflammation. Genetic and pharmacological interventions have resulted in partial suppression of the neuroinflammatory responses to MPTP and METH without affecting neurotoxicity and gliosis. In an attempt to achieve a complete suppression of neuroinflammation, chronic exposure to corticosterone (CORT) was used. Surprisingly, mice treated with CORT exhibited an exaggerated neuroinflammatory response to METH coupled with potentiated neurotoxicity (loss of dopaminergic nerve terminal marker, tyrosine hydroxylase) and gliosis. As the levels of chronic CORT approached or exceeded those associated with high physiological stress, the data suggest chronic CORT therapy or sustained physiological stress sensitizes CNS neuroinflammatory and neurotoxic responses. Yet, in a model of LPS-induced systemic infection that does not induce gliosis or neural damage, chronic CORT pretreatment greatly exacerbated and prolonged neuroinflammation without evidence of neural damage or gliosis. These results show a priming of the CNS proinflammatory response to amplify future exposures to pathogens, injury or toxicity. Taken together these findings suggest that while neurotoxicity causes inflammation, neuroinflammation may potentiate, but does not necessarily cause, neurotoxicity.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.